A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens

Abstract Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapolation from a noncompartmental analysis (NCA) with a t...

Full description

Bibliographic Details
Main Authors: Lisa van derHeijden, Merel vanNuland, Jos Beijnen, Alwin Huitema, Thomas Dorlo
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13446
_version_ 1811164880671080448
author Lisa van derHeijden
Merel vanNuland
Jos Beijnen
Alwin Huitema
Thomas Dorlo
author_facet Lisa van derHeijden
Merel vanNuland
Jos Beijnen
Alwin Huitema
Thomas Dorlo
author_sort Lisa van derHeijden
collection DOAJ
description Abstract Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapolation from a noncompartmental analysis (NCA) with a two‐fold acceptance criterion between pharmacokinetic metrics of the extrapolated microdose and the therapeutic dose. The major disadvantage of NCA is the assumption of linear extrapolation of NCA metrics. In this study, we used a naïve pooled data (NPD) modeling approach to extrapolate microdose pharmacokinetics to therapeutic pharmacokinetics. Gemcitabine and anastrozole were used as examples of intravenous and oral drugs, respectively. Data from microdose studies were used to build a parent‐metabolite model for gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine (dFdU) and a model for anastrozole. The pharmacokinetic microdose models were extrapolated to therapeutic doses. Extrapolation of the microdose showed differences in pharmacokinetic shape for gemcitabine and dFdU between the simulated and observed therapeutic concentrations, whereas the observed therapeutic concentrations for anastrozole were captured by the extrapolation. This study demonstrated the possible use and feasibility of an NPD modeling approach for the evaluation and application of microdose studies in early drug development. Last, physiologically‐based pharmacokinetic modeling might be an alternative for microdose extrapolation of drugs with complex pharmacokinetics such as gemcitabine.
first_indexed 2024-04-10T15:29:24Z
format Article
id doaj.art-aaf34c4b3c5a4baf998072fbc42281c1
institution Directory Open Access Journal
issn 1752-8054
1752-8062
language English
last_indexed 2024-04-10T15:29:24Z
publishDate 2023-02-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj.art-aaf34c4b3c5a4baf998072fbc42281c12023-02-14T07:32:57ZengWileyClinical and Translational Science1752-80541752-80622023-02-0116225826810.1111/cts.13446A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimensLisa van derHeijden0Merel vanNuland1Jos Beijnen2Alwin Huitema3Thomas Dorlo4Department of Pharmacy & Pharmacology Antoni van Leeuwenhoek/The Netherlands Cancer Institute Amsterdam The NetherlandsDepartment of Pharmacy & Pharmacology Antoni van Leeuwenhoek/The Netherlands Cancer Institute Amsterdam The NetherlandsDepartment of Pharmacy & Pharmacology Antoni van Leeuwenhoek/The Netherlands Cancer Institute Amsterdam The NetherlandsDepartment of Pharmacy & Pharmacology Antoni van Leeuwenhoek/The Netherlands Cancer Institute Amsterdam The NetherlandsDepartment of Pharmacy & Pharmacology Antoni van Leeuwenhoek/The Netherlands Cancer Institute Amsterdam The NetherlandsAbstract Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapolation from a noncompartmental analysis (NCA) with a two‐fold acceptance criterion between pharmacokinetic metrics of the extrapolated microdose and the therapeutic dose. The major disadvantage of NCA is the assumption of linear extrapolation of NCA metrics. In this study, we used a naïve pooled data (NPD) modeling approach to extrapolate microdose pharmacokinetics to therapeutic pharmacokinetics. Gemcitabine and anastrozole were used as examples of intravenous and oral drugs, respectively. Data from microdose studies were used to build a parent‐metabolite model for gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine (dFdU) and a model for anastrozole. The pharmacokinetic microdose models were extrapolated to therapeutic doses. Extrapolation of the microdose showed differences in pharmacokinetic shape for gemcitabine and dFdU between the simulated and observed therapeutic concentrations, whereas the observed therapeutic concentrations for anastrozole were captured by the extrapolation. This study demonstrated the possible use and feasibility of an NPD modeling approach for the evaluation and application of microdose studies in early drug development. Last, physiologically‐based pharmacokinetic modeling might be an alternative for microdose extrapolation of drugs with complex pharmacokinetics such as gemcitabine.https://doi.org/10.1111/cts.13446
spellingShingle Lisa van derHeijden
Merel vanNuland
Jos Beijnen
Alwin Huitema
Thomas Dorlo
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
Clinical and Translational Science
title A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
title_full A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
title_fullStr A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
title_full_unstemmed A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
title_short A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
title_sort naive pooled data approach for extrapolation of phase 0 microdose trials to therapeutic dosing regimens
url https://doi.org/10.1111/cts.13446
work_keys_str_mv AT lisavanderheijden anaivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT merelvannuland anaivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT josbeijnen anaivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT alwinhuitema anaivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT thomasdorlo anaivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT lisavanderheijden naivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT merelvannuland naivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT josbeijnen naivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT alwinhuitema naivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens
AT thomasdorlo naivepooleddataapproachforextrapolationofphase0microdosetrialstotherapeuticdosingregimens